Published ahead of print on December 30, 2004, doi:10.1165/rcmb.2004-0325OC
© 2005 American Thoracic Society DOI: 10.1165/rcmb.2004-0325OC Upregulation of Hypoxia-Induced Mitogenic Factor in Compensatory Lung Growth after PneumonectomyDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Surgery, University of Virginia Health System, Charlottesville, Virginia Correspondence and requests for reprints should be addressed to Dechun Li, M.D., Ph.D., Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 600 N. Wolfe St., Blalock 1404A, Baltimore, MD 21205. E-mail: dechunli{at}jhmi.edu
After pneumonectomy, the remaining lung increases in size. This process is referred to as compensatory lung growth. Various pathways likely play important roles in this growth response. The molecular mechanisms involved in compensatory lung growth, however, remain poorly understood. Hypoxia-induced mitogenic factor (HIMF), also called FIZZ1 or RELM- , possesses mitogenic, vasoconstrictive, angiogenic, and antiapoptotic effects. In this study, we examined the expression of HIMF in mouse lung after pneumonectomy to test the hypothesis that HIMF expression is upregulated during compensatory lung growth. Results showed that HIMF is upregulated from Day 1 after pneumonectomy and peaking at Day 7 in the lung. HIMF upregulation is temporally and spatially related to lung cell proliferation, as demonstrated by expression of proliferating cell nuclear antigen. Immunohistochemical staining and in situ hybridization showed that upregulated HIMF protein and mRNA are mainly distributed in airway epithelium, alveolar type II cells, and endothelial cells of the pulmonary vessels. Intratracheal instillation of recombinant HIMF resulted in widespread cell proliferation, including airway epithelium, alveolar type II cells, and cells in the alveolar septa. These results indicate a new role for HIMF in compensatory lung growth, which is that HIMF may act as a lung-specific growth factor and participate in lung regeneration after pneumonectomy.
Key Words: compensatory lung growth hypoxia-induced mitogenic factor mouse pneumonectomy
After pneumonectomy in experimental animals, the remaining lung rapidly increases in size (14). This adaptive growth, referred to as compensatory lung growth, results in restoration of essentially normal lung cell populations, alveolar number, and total lung volume, compliance, mass, DNA, protein, alveolar and capillary surface areas, and lung function (59). Children and adolescents subjected to unilateral pneumonectomy also develop a varying degree of compensatory growth in the contralateral lung (10). The extent of compensatory growth achieved is reduced with increased age, but if lung tissue is removed sufficiently early in life, there is nearly complete restitution of the lung. Various pathways likely play important roles in this growth response, including changes in lung inflation, blood flow, hypoxia, and release of growth-promoting substances, such as growth factors, nitric oxide, retinoic acid, and adrenal hormones (1115). The molecular mechanisms involved in compensatory lung growth, however, are not understood. Successful compensatory lung growth is likely to require the coordinated expression of various growth factors and their receptors, directed at the different cell types within the lung, acting through autocrine, endocrine, juxtacrine, or paracrine pathways (1518). Despite extensive literature relating to experimental pneumonectomy, the mediators of compensatory lung growth in the remaining lung tissue have not been elucidated.
This study focused on the role of hypoxia-induced mitogenic factor (HIMF) in compensatory lung growth after pneumonectomy. From a mouse model of hypoxia-induced pulmonary hypertension, we previously found a highly upregulated gene that we named HIMF (19). HIMF has an identical amino acid sequence to a protein called FIZZ1, identified in a mouse lung inflammation model (20), and RELM- To date, there have been no studies related to the function of HIMF in compensatory lung growth, and its biological function and roles in the pulmonary system are still largely unknown. Previous studies from our laboratory demonstrated that recombinant HIMF has mitogenic, angiogenic, and vasoconstrictive effects that can: (1) induce pulmonary microvascular smooth muscle cell proliferation, (2) induce pulmonary vessel constriction (which is more potent than endothelin-1 and serotonin), (3) induce endothelial cell migration, and (4) promote endothelial cell tubule formation (19). In the developing lung, HIMF has been shown to be highly expressed in the perinatal period and also possesses an antiapoptotic function in cultured embryonic lungs (22). Because HIMF is a secreted and inducible protein in the lung, it is possible to speculate that HIMF may act in an autocrine or paracrine fashion in the lung. However, because the putative receptor for HIMF is still elusive, the exact mechanism and signaling pathways in HIMF-induced biological effects are still unidentified. In the present study, we tested the hypothesis that HIMF expression is upregulated during the compensatory growth process of the lung. We found HIMF to be highly upregulated in compensatory lung growth, especially during the early hyperplastic period (17 d) after pneumonectomy. During that period, the remaining lung cells proliferate vigorously and restore the lost lung parenchyma. Moreover, intratracheal instillation of recombinant HIMF protein induced widespread cell proliferation in the lung, including airway epithelial cells, alveolar type II cells, and vascular endothelial and smooth muscle cells. These findings indicate that HIMF may be a lung-specific growth factor participating in lung cell proliferation and modulation of compensatory lung growth after pneumonectomy.
Animal Model of Pneumonectomy All animals were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) intraperitoneally along with an injection of 0.5 ml saline to alleviate any blood volume loss. Left pneumonectomy and sham surgeries were performed as previously described (11). The sham surgery was essentially a left thoracotomy without removal of the lung to serve as a surgical control group. Each mouse was shaved along the left lateral chest followed by endotracheal intubation with a 24-gauge catheter. All animals were mature, age-matched (1416 wk) male C57BL6 mice weighing 25 g each (11). Mice were divided into two groups: sham controls (7 d after surgery, S7d, n = 6); and pneumonectomy. The pneumonectomy group was then subdivided into five subgroups on the basis of the postoperative survival times: immediate (Time 0), 1 d, 3 d, 5 d, 7 d, and 14 d (n = 8/group). Preliminary experiments have shown that there was no significant increase of HIMF protein in the sham-operated animal lungs compared with normal mouse lungs at all the designated time points. Thus we used only the Day 7 group of sham animal lungs in the Western blot as an example. All the experimental procedures were approved by the Animal Care and Use Committees of the Johns Hopkins University and the University of Virginia Health System.
Measurement of Total Lung Weight and Lung Weight Index
Immunohistochemical Staining for HIMF and Proliferating Cell Nuclear Antigen
Western Blot for HIMF, PCNA, and ß-Actin in Lung Homogenates
In Situ Hybridization for Localization of HIMF mRNA in the Postpneumonectomy Mouse Lung
Northern Blot Analysis for HIMF mRNA
Intratracheal Instillation of HIMF
Statistical Analysis
Pneumonectomy As expected, there was significant reduction of the lung tissues in the pneumonectomy animals compared with the sham control animals. Figure 1A shows that there was a significant amount of lung tissue removed by pneumonectomy (P < 0.001, sham 7 d total lung weight compared with Day 0 and Day 1 right lung after pneumonectomy). However, left pneumonectomy resulted in a significant increase in the right lung weight beginning at Day 3 after pneumonectomy. By Day 14, the right lung weight had reached the same level as that in sham control animals. Figure 1B shows that after pneumonectomy, LWI started to significantly increase at Day 3, and reached high levels after 514 d (a 33.4% increase of LWI at Day 14 after surgery).
Western Blot Analysis of HIMF, PCNA, and ß-Actin Although we previously reported a prominent role of HIMF in adult and developing mouse lung (19, 22), it was not known if HIMF is expressed in the regenerating lung after pneumonectomy. To examine HIMF expression after pneumonectomy, lung protein homogenates were subjected to polyacrylamide gel electrophoresis and subsequently detected by Western analysis using the respective antibodies to HIMF, PCNA, and ß-actin for loading control (Figure 2). As predicted, HIMF protein expression was very low in Day 0 lungs, and sham surgery did not alter this expression. However, pneumonectomy induced significant upregulation of HIMF protein expression. HIMF first emerged at Day 1 with a slight but significant increase (P < 0.05 compared with Day 0 and sham), and gradually peaked to the highest levels at Day 7 (Figures 2A and 2B). At 14 d after pneumonectomy, HIMF level was reduced but was still higher than Day 0 and sham groups. Most interestingly, HIMF expression paralleled with upregulation of PCNA expression in the regenerating mouse lung, which also peaked at Day 7 after pneumonectomy (Figures 2A and 2C).
HIMF and PCNA Immunohistochemistry To elucidate the localization of cells expressing HIMF within the lung during compensatory lung growth, immunohistochemical staining of HIMF and PCNA was performed. Immunohistochemical staining of HIMF confirmed the induction of HIMF in the lung after pneumonectomy (Figure 3). Consistent with previous reports of HIMF protein localization in the lung (19, 21), the results showed that HIMF protein was restricted to the airway epithelial cells, alveolar type II cells, and endothelial cells of the pulmonary vessels (Figure 3). Most interestingly, the number of PCNA-positive cells was also enhanced after pneumonectomy, and these cells were also largely airway epithelial cells, alveolar type II cells, and endothelial cells of the pulmonary vessels (Figure 4), indicating the overlapping of HIMF and PCNA temporal and spatial expression. Furthermore, using consecutive sections stained with HIMF and PCNA separately, we demonstrated that HIMF and PCNA are expressed in the same cells (airway epithelial cells and alveolar type II cells) to further support the idea that HIMF may stimulate cell proliferation in an autocrine and paracrine fashion (Figure 5).
Fluorescent In Situ Hybridization for HIMF Fluorescent in situ hybridization (FISH), using 6-carboxyfluoresceinlabeled sense and antisense HIMF oligoprobes, demonstrated HIMF mRNA upregulation after pneumonectomy (Figure 6). The results showed that, in the sham lung (at Day 7 after surgery), the weakly positive HIMF mRNA signal only appeared in airway epithelial cells and a few alveolar type II cells (Figure 6A). In the lungs from Days 3, 7, and 14 after pneumonectomy, a strong positive HIMF signal was localized in airway epithelia and alveolar type II cells (Figures 6B6D depict Day 7 lungs). These results agree with the immunohistochemical staining and Western blot results, and indicate that HIMF expression is largely controlled at the transcriptional level. Furthermore, because HIMF was highly upregulated during the proliferating period of lung growth, it may play an important role in the control of hyperplastic lung regeneration.
Northern Blot for HIMF Consistent with the FISH results in the regenerating lung, Northern blot analysis showed that the sham control had very low levels of HIMF expression (Figure 7). Pneumonectomy dramatically increased HIMF mRNA at Day 1 and peaked at Day 7 after surgery, and then was reduced to a low level at Day 14 (Figure 7). These changes paralleled the HIMF protein expression (see Figures 2 and 3) and indicate that HIMF gene expression is controlled at the transcriptional level.
Intratracheal Instillation of HIMF Lung tissues were collected 3 and 5 d after intratracheal instillation of HIMF into unoperated mice, and the slides were examined for PCNA-positive cells. Immunohistochemical staining of PCNA showed that in the FLAG controls, the PCNA-positive cells were rarely seen in the airway epithelium and in the lung parenchyma (Figures 8A and 8B). However, HIMF instillation induced widespread cell proliferation in the lung, including airway epithelial cells, alveolar type II cells, endothelial cells of the pulmonary vasculature, and the cells of the alveolar septa, both in the Day 3 (Figures 8C and 8D) and Day 5 groups (Figures 8E and 8F). The PCNA-positive cells were mostly seen in the proximal airways and the lung tissues surrounding them. These data support the hypothesis that HIMF stimulates lung hyperplasia after pneumonectomy, possibly by promoting epithelial and parenchymal cell proliferation. In addition, there was no difference detected between the intensity of PCNA staining in the cells of pneumonectomy and intratracheal HIMF-treated lung sections.
The treatment of certain lung diseases or conditions, such as cancer, emphysema, or severe trauma, often requires pneumonectomy or lobectomy. It has been shown, not only in experimental animals but also in humans, particularly in infants or young children, that removal of lung tissue often results in compensatory growth of the remaining lung (1, 2, 18, 26, 27). In addition, various scenarios, such as reduced-size lung transplantation and pulmonary insufficiency, can benefit from the modulation and induction of lung growth (4, 15). Extensive animal studies have enhanced our knowledge of this process, and a better understanding of the mechanisms of lung growth will undoubtedly facilitate lung regeneration to accelerate restoration of lung function. The molecular mechanisms of compensatory lung growth, however, are still largely unknown. Many reports have illustrated the importance of various factors involved in regulation of compensatory lung growth, including mechanical strain (28), hypoxia (29), growth factors (16, 24), retinoic acid (23), and nitric oxide (11). A previous study in our laboratory showed that keratinocyte growth factor (KGF) enhances postpneumonectomy lung growth by alveolar proliferation (24). In that study, it was found that administration of KGF to adult rats resulted in significantly enhanced LWI, lung volume index, cell proliferation index, and total volume of respiratory region after pneumonectomy but not after sham surgery, suggesting that KGF can induce new alveolar formation in mature lung. In the current study, we examined the expression of HIMF in compensatory lung growth. We found that HIMF protein and mRNA are highly upregulated in the regenerating lung after pneumonectomy, especially in the first 7 d. HIMF protein was localized to airway epithelial cells, alveolar type II cells, and, occasionally, to vascular endothelial cells. Most importantly, HIMF expression paralleled with PCNA expression, and both HIMF and PCNA immunostaining were localized in the same populations of cells. Using consecutive-section staining with HIMF and PCNA, we have identified the cells expressing both proteins simultaneously, including airway epithelial cells and alveolar type II cells. These results strongly support the idea that HIMF, as a lung-specific, inducible growth factor, may stimulate lung cell proliferation in an autocrine or paracrine fashion in the compensatory growing lung. In addition, intratracheal instillation of recombinant HIMF protein induced wide-spread proliferation of airway epithelial cells, alveolar type II cells, and cells in the lung parenchyma. These results support the idea that HIMF is not only a mitogenic factor to pulmonary microvascular smooth muscle cells (19), but is also a lung-specific growth factor that participates in compensatory lung growth after pneumonectomy. Previous studies have demonstrated that HIMF is also a potent vasoconstrictor that can significantly raise pulmonary arterial pressure (19). HIMF-induced pulmonary arterial pressure increase is more potent than the common vasoactivators, such as endothelin-1, angiotensin II, and serotonin, but less potent than the thromboxane mimetic U-46619. However, we cannot exclude the possibility of a vasoconstrictive effect during upregulation of HIMF in compensatory lung growth. Moreover, HIMF also possesses an angiogenic function that promotes vascular tube formation in a matrigel plug model (19). More recently, we reported that HIMF is developmentally regulated in mouse lung, particularly during the perinatal period, and that HIMF also has an antiapoptotic effect in cultured embryonic lung (22). As we have shown here, intratracheally instilled HIMF stimulated a variety of cell proliferation in the airways and in the parenchyma of the lung (Figure 8). It is conceivable to postulate that HIMF, as a secreted and inducible lung-specific growth factor mainly from airway epithelial cells and alveolar type II cells, may act through its receptor. HIMF upregulation in the postpneumonectomy lung facilitates growth by stimulating proliferation in a variety of cell types via its receptor in an autocrine or paracrine fashion. However, the identification of the HIMF receptor is still elusive, and the detailed mechanism of HIMF upregulation and HIMF-induced cell proliferation remains unclear. As we have shown, HIMF-induced pulmonary microvascular smooth muscle cell proliferation is partially mediated by PI3K/Akt signal transduction pathway (19), but whether Akt activation participates in compensatory lung growth through HIMF receptors is currently unknown. It has been speculated that the process of compensatory lung growth potentially involves the same signaling mechanisms that participate in normal postnatal alveolarization in the lung (15, 17, 24). HIMF might be one such signaling factor, as we have described the upregulation of HIMF in both compensatory lung growth (the present study) and the developing lung (22). We speculate that HIMF upregulation is a partially reserved process to recapitulate normal postnatal lung maturation, and upregulated HIMF may be a specific mediator of compensatory lung growth by contributing to alveolar formation and lung maturation. Consistent with this speculation, intratracheal instillation of recombinant HIMF stimulated lung cell proliferation, as ascertained by PCNA immunohistochemistry both in the airway epithelial cells and in the lung parenchyma. In summary, we have shown that HIMF expression is induced in compensatory lung growth and that intratracheal instillation of HIMF protein induced wide-spread cell proliferation in the mouse lung. In addition, HIMF and PCNA expression localize spatially and temporally in airway epithelial cells, alveolar type II cells, and parenchymal cells of the alveolar septa after pneumonectomy. These results suggest that upregulation of HIMF may play an important role in compensatory lung growth after pneumonectomy. The determination of the functional role of HIMF in regenerating lung warrants further investigation that will ultimately contribute to a better understanding of postnatal lung growth.
This work was supported by National Institutes of Health RO1 grants HL75755 (D.L.) and HL67780 (V.E.L.). Conflict of Interest Statement: D.L. has no declared conflicts of interest; L.G.F. has no declared conflicts of interest; J.D. has no declared conflicts of interest; J.L. has no declared conflicts of interest; D.W. has no declared conflicts of interest; and V.E.L. has no declared conflicts of interest. Received in original form October 13, 2004 Received in final form December 2, 2004
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||